Expertise & Services

Expertise

Our Functional Genomics core has proven expertise in designing experiments to develop and test pre-clinical treatment strategies using validated models that recapitulate human biology. Model systems are used for validation of novel therapeutics designed to target genetic and molecular aberrations associated with aggressive prostate cancer that are identified using next-generation sequencing in human tumour and circulating free DNA samples.

Services

The Functional Genomics Core provides valuable tools with high clinical relevance for studying the molecular and cellular development and progression of prostate cancer, including:

  • Rapid and comprehensive evaluation of novel small molecules and biologics in preclinical model systems including:
    • Cytotoxicity assays
    • Clonogenic assays
    • Biomarker assays (established or novel)
    • Drug-target and off-target interaction assays
    • Drug-drug interactions
    • in vitro and in vivo tumour cell lines
  • An existing variety of cell lines and models (xenograft and transgenic) including:
    • models for disease progression from androgen dependent to castrate resistant prostate cancer
    • tumors/cells resistant to newly approved AR antagonist enzalutamide 
    • novel first-in-field neuroendocrine trans-differentiation patient-derived xenografts
  • Fully functioning suites for the generation and analysis of xenografts, transgenics and PDXs
  • Liquid nitrogen tanks for storage of patient and PDX tissue
  • Preparation and in vivo application of gene targeting techniques to test pre-clinical efficacy of novel anti-cancer agents, including:
    • antisense oligonucleotides (ASOs, siRNA)
    • novel small molecule or antibody inhibitors
    • novel combination therapies
  • Viral delivery for gain-of-function analyses
  • Antisense/RNAi/CRISPR-Cas9 technology for loss-of-function analyses

The Living Tumour Laboratory

The Living Tumor Lab is a unique and valuable resource, which grows a wide variety of patient-derived cancer tissues, including both low and high-grade solid cancers. This work enables researchers to readily study human cancer tissue in vivo, and develop a variety of transplantable tumour tissue lines that can be used as models for studying cancer growth/progression/metastasis and drug sensitivity.

For more information visit www.livingtumorlab.com

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Conference Flyer Page 1

Breast & Prostate Cancer half-day virtual conference: Saturday, September 18th, 2021

The What you Need to Know for Your Patients Post Breast & Prostate Cancer Conference, taking place online on Saturday, September 18th, 2021 from 8:00am – 1:30pm, is an accredited virtual half-day conference focusing on screening, treatment, side-effect management & emerging new therapies for breast & prostate cancer patients. Click here for more information and to register. 

Dr. Peter Black, team captain

Terry Fox Run fundraiser: September 19th, 2021

The 41st Annual Terry Fox Run is taking place on Sunday September 19, 2021. If you are able, please consider donating to our team (tax receipts issued), raising funds for the Terry Fox Foundation's ground-breaking cancer research. 

Employment

Work at the Vancouver Prostate Centre

Wednesday, September 8, 2021

Recent publication proposes a potential new therapeutic approach to treatment-resistant prostate cancer

Tuesday, August 3, 2021

Dr. Cherkasov receives 2021 Faculty of Medicine Distinguished Achievement Award

Dr. Cherkasov